Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016;10(3):371-382.
doi: 10.1586/17474124.2016.1121810. Epub 2016 Jan 6.

Proposed therapies in primary biliary cholangitis

Annarosa Floreani #  1 , Ying Sun #  2   3 , Zheng Sheng Zou  3 , Baosen Li  3 , Nora Cazzagon  1 , Christopher L Bowlus  4 , M Eric Gershwin  2
Affiliations
Review

Proposed therapies in primary biliary cholangitis

Annarosa Floreani et al. Expert Rev Gastroenterol Hepatol. 2016.

Abstract

Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is a model autoimmune disease with chronic cholestasis characterized by the hallmark of anti-mitochondrial antibodies and treated with ursodeoxycholic acid (UDCA). However, approximately 20-40% of patients incompletely respond to UDCA and have an increased risk of disease progression. Although there have been significant advances in the immunobiology of PBC, these have yet to be translated into newer therapeutic modalities. Current approaches to controlling the immune response include broad immunosuppression with corticosteroids as well as targeted therapies directed against T and B cells. In contrast, ameliorating cholestasis is the focus of other therapies in development, including obeticholic acid. In this article the authors will discuss ongoing clinical trials and, in particular, the rationale for choosing agents that may effectively target the aberrant immune response.

Keywords: Primary biliary cirrhosis; UDCA; biologic agents; budesonide; fatigue; fibrates; obeticholic acid; pruritus; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Targets of pruritus in cholestasis.
See this image and copyright information in PMC

References

    1. Gershwin ME, Mackay IR, Sturgess A, et al. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol. 1987;138:3525–31. [Original paper reporting the identification of the antimitochondrial antibody antigen.] - PubMed
    1. Beuers U, Gershwin ME. Unmet challenges in immune-mediated hepatobiliary diseases. Clin Rev Allergy Immunol. 2015;48:127–31. - PubMed
    1. Bian Z, Miao Q, Zhong W, et al. Treatment of cholestatic fibrosis by altering gene expression of Cthrc1: Implications for autoimmune and non-autoimmune liver disease. J Autoimmun. 2015 - PMC - PubMed
    1. Han Y, Jiang Z, Chen Z, et al. Pathogen-expanded CD11b+ invariant NKT cells feedback inhibit T cell proliferation via membrane-bound TGF-beta1. J Autoimmun. 2015;58:21–35. - PubMed
    1. Hirschfield GM, Siminovitch KA. Genetics in PBC: what do the “risk genes” teach us? Clin Rev Allergy Immunol. 2015;48:176–81. - PubMed

Publication types

MeSH terms